Glutamate and ␥-amino butyric acid (GABA) systems are emerging as targets for development of medications for mood disorders. There is increasing preclinical and clinical evidence that antidepressant drugs directly or indirectly reduce N-methyl-D-aspartate glutamate receptor function. Drugs that reduce glutamatergic activity or glutamate receptor-related signal transduction may also have antimanic effects. Recent studies employing magnetic resonance spectroscopy also suggest that unipolar, but not bipolar, depression is associated with reductions in cortical GABA levels. Antidepressant and mood-stabilizing treatments also appear to raise cortical GABA levels and to ameliorate GABA deficits in patients with mood disorders. The preponderance of available evidence suggests that glutamatergic and GABAergic modulation may be an important property of available antidepressant and mood-stabilizing agents. Future research will be needed to develop and evaluate new agents with specific glutamate and GABA receptor targets in the treatment of mood disorders. Molecular Psychiatry (2002) 7, S71-S80.
Introduction
It is timely to consider the role of glutamate and ␥-amino butyric acid (GABA) systems in the pathophysiology and treatment of mood disorders. Over the past 35 years, a focus on monoaminergic contributions to the neurobiology of mood disorders has yielded a broad range of pathophysiological insights. 1 Further, this focus contributed to the development of a growing number of antidepressant classes, including the tricyclic antidepressants, monoamine oxidase inhibitors, serotonin reuptake inhibitors, monoamine receptor antagonists (eg, trazodone, mirtazapine) and bupropion. 2 A focus on monoaminergic neurotransmission also generated medication augmentation or combination approaches to enhance the efficacy of antidepressant treatment. However, there is a need to examine the contribution of other systems to the neurobiology and treatment of depression. 3 Monoamine depletion paradigms, for example, failed to find a 'final common pathway' for antidepressant efficacy. Similarly, molecular neuroscience advances highlight the potential importance of intracellular signal transduction cascades and neurotophin-related mechanisms Correspondence: JH Krystal, Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06519, USA. E-mail: john.krystal Ȱyale.edu in depression and its treatment. 4 With respect to bipolar disorder, a premature focus on the monoaminergic effects of lithium, anticonvulsants and L-type calcium channel antagonists might preclude a careful consideration of their other effects. 5 In the context of the search for novel pathogenic and therapeutic mechanisms for mood disorders, glutamatergic and GABAergic systems now deserve reconsideration. 6, 7 This review will make three principal points: N-methyl-D-aspartate (NMDA) glutamate receptor antagonists may be antidepressant; drugs that reduce or prevent glutamatergic activation in some experimental paradigms may have antidepressant or mood-stabilizing activity; and treatments for unipolar depression may normalize a cortical GABA deficit.
Glutamatergic agents as antidepressants and mood stabilizers

Glutamatergic abnormalities in mood disorders
Abnormalities in glutamatergic circuitry are suggested by antemortem and postmortem evidence of structural and functional abnormalities in patients with unipolar and bipolar depression. Structural and functional neuroimaging studies have described volume reductions in cortical, limbic, striatal and cerebellar structures and regional alterations in activity. [8] [9] [10] [11] [12] Volume reductions in the subgenual region of the prefrontal cortex were found in both unipolar and bipolar disorder patients with a family history of mood disorder. 13 The magnetic resonance imaging findings were consistent with postmortem studies' reductions in glial populations in subgenual frontal cortex 14 or decreases in both neuronal and glial cell number and size in orbital or dorsolateral prefrontal cortex. 15 Glial deficits in mood disorders, not anticipated by earlier pathophysiological models, could cause a complex disturbance in glutamatergic regulation (Figure 1 ). Glia bear glutamate transporters and glial glutamate uptake is the primary mechanism for removing glutamate from the synapse. 16, 17 Deficits in glia function, as are found in some types of epilepsy, appear to be associated with dysfunctional, or even toxic, accumulations of synaptic glutamate. 18 Glial deficits, therefore, could contribute to increased regional cerebral metabolism observed in mood disorders. [19] [20] [21] Glia also release D-serine in response to stimulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptors. 22 D-serine stimulates the glycine-B coagonist site of the NMDA receptor. Thus, glial loss could contribute to reductions in NMDA receptor function. Glia also play an important role in providing neurons with lactate, an important substrate for energy metabolism. 17 Mismatches between excitatory drive and energetic supply may promote atrophy and neurotoxicity. 23 Thus, glial deficits might produce a mix of Figure 1 Schematic depiction of the interplay of neuronal and glial elements involved in glutamate neurotransmission. Presynaptic neurons release glutamate from a pool that is primarily derived from glutamine recycled from glia. Once released, glutamate binds to postsynaptic 'effector' glutamate receptors, including NMDA and AMPA receptors. Glutamate also binds to AMPA receptors on glia that stimulate the release of D-serine, an NMDA receptor co-agonist. Glutamate binds to glutamate transporters, primarily on glia, an action that stimulates the removal of glutamate from the synapse. Glutamate uptake, in turn, activates intracellular processes that result in the stimulation of the glial uptake of glucose. This glucose undergoes glycolysis within the glia, and lactate is shuttled to the neuron, where it is converted to pyruvate and enters the tricarboxylic acid cycle (TCA). Alpha-ketoglutarate, a TCA intermediate, is converted to glutamate. In glutamate neuron, this glutamate synthesis may serve as a secondary source for glutamate that is released by neurons. In GABA neurons, newly synthesized glutamate may be converted to GABA.
glutamatergic hyperactivity and deficits in NMDA receptor function and cellular energy supply. Functional characterization of glutamatergic dysregulation in mood disorders paralleled recent structural studies. For example, one pilot study found that euphoria and disruption of working memory produced by an NMDA antagonist were increased in unipolar depressed patients compared with healthy controls. 24 A postmortem study in suicide victims also reported down-regulation of high-affinity glycine binding to the NMDA receptor in the frontal cortex of suicide victims. 25 Preliminary results from two magnetic resonance spectroscopy (MRS) studies suggest that occipital cortex glutamate turnover is reduced in patients with unipolar, but not bipolar, depression. In the first study, occipital cortex glutamate levels were assessed with 1 H-MRS. 26 The elevation in cortical glutamate levels in this study correlated inversely with GABA levels within this region and positively with the levels of the neuronal metabolite, N-acetyl-aspartate. Glutamate levels measured with 1 H-MRS reflect total tissue glutamate content, including glutamate in non-neuronal elements and metabolic pools. Increases in glutamate concentration within the pool of glutamate that might be released into the synapse might indicate a reduction in glutamate turnover (Figure 1 ). To draw this inference with MRS-based technologies, one must employ 27, 28 Preliminary results generated using this approach find no increases or even decreases in occipital cortex glutamate turnover in patients with unipolar depression. 29 Consistent with studies of glucose metabolism reviewed earlier, mood disorders may be associated with regionally specific alterations in glutamate turnover rates. For example, another 1 H-MRS study 30 reported the opposite pattern-reductions in glutamate levels-in the anterior cingulate in depressed patients. 31 In the latter studies, NMDA receptor antagonists had dose-related effects that were comparable in magnitude, but more rapid, than imipramine. The mechanisms through which NMDA receptor antagonists exerted this effect are not yet clear. For example, NMDA antagonists down-regulated ␤-adrenergic receptors, similar to other antidepressants. 32 NMDA receptor antagonists also enhance serotonergic function. [33] [34] [35] [36] Alternatively, increases in the affinity of the glycine-B site of the NMDA receptor 37 and increases in the level of both NMDA and AMPA receptor subunits 38 have been reported in some animal stress paradigms. NMDA receptor blockade might reduce the consequences of these effects.
Down-regulation of the glycine-B site of NMDA receptors appears to be a common feature of current antidepressant medications. As shown in Figure 2 , tricyclics, serotonin reuptake inhibitors, electroconvulsive stimuli and bupropion, but not other classes of treatments, reduced the potency of glycine to inhibit [ 3 H]-5,7-dichlorkynurenic acid (5,7-DCKA) binding to the glycine-B site of the NMDA receptor, a change consistent with down-regulation of the NMDA receptor function. 39 In this study, the NMDA antagonist, ketamine, did not modify sensitivity to glycine, although it directly reduced NMDA receptor function through blockade of the calcium channel within the NMDA receptor complex. The tricyclic antidepressant, desipramine, which has direct NMDA receptor antagonism at therapeutic doses, 40, 41 reduces the potency of glycine to displace 5,7-DCKA binding similarly to other antidepressants, and it also reduces the density of 5,7-DCKA binding sites. 39 In humans, the antidepressant activity of NMDA receptor antagonists received little rigorous evaluation. The initial clue came from studies of D-cycloserine (DCS), an antibiotic developed to treat tuberculosis. 42 In preclinical studies, DCS, at maximally stimulating doses, produces roughly half of the maximal facilitation of NMDA receptor function associated with glyMolecular Psychiatry cine. 43, 44 Under conditions where the occupancy of glycine-B sites by agonists exceeds 50%, glycine-B antagonist-like effects emerge. 45 This antagonist-like effect of DCS is reflected in an increase in the off-rate for glutamate from the NMDA receptor. 46 Crane 42, 47 reported evidence of DCS antidepressant effects in depressed tuberculosis patients. Beneficial effects of DCS in doses of 500 mg day −1 occurred in a high proportion of the patients studied with respect to depressed mood, insomnia and reduced appetite. Rapid onset of antidepressant activity was a striking feature of DCS effects in these patients. At the doses employed to treat tuberculosis, DCS has mild acute, dose-related euphoric and amnestic effects in humans that resemble the effects of subperceptual doses of noncompetitive NMDA antagonists. 48, 49 Thus, the antidepressant effects of DCS may reflect consequences of its capacity to reduce NMDA receptor function.
Additional evidence of the antidepressant activity of NMDA receptor antagonists comes from case reports and studies suggesting that amantadine has clinical efficacy. 50 Amantadine is a low-affinity uncompetitive antagonist of NMDA receptor. At high doses, amantadine reduces NMDA receptor function by approximately 50%, an effect attributed to its instability within the NMDA receptor calcium channel. [51] [52] [53] This drug showed evidence of antidepressant activity in unipolar and bipolar depressed patients and in depressed patients with Parkinson disease (Table 1) . [54] [55] [56] [57] Amantadine was developed initially as an antiviral agent, in part due to its ability to reduce the entry of viruses into cells. This action has stimulated interest in the possibility that NMDA receptor antagonists may attenuate 50 A related NMDA receptor antagonist, memantine, shows signs of behavioral improvement across a number of dimensions in patients with Alzheimer's disease. 58, 59 Most recently, a placebo-controlled pilot study suggested that the administration of single doses of ketamine 0.5 mg kg −1 , intravenously, had antidepressant effects in depressed patients. 60 As shown in Figure 3 , ketamine infusion produced mild psychosis and euphoria that dissipated within 120 min. In contrast, the antidepressant effects of ketamine infusion emerged over the first 180 min and persisted over 72 h. Within this study, some patients reported antidepressant effects lasting as long as a week.
The clinical evidence supporting the antidepressant efficacy of NMDA antagonists is scanty. However, if effective, NMDA antagonists may show unique onset rapidity of clinical efficacy. Thus, further evaluation of this drug class in the treatment of depression would seem to be a high priority.
Evidence that mood stabilizers attenuate corticolimbic glutamate release or its postsynaptic consequences
The capacity to treat symptoms of both depression and mania is an important feature of mood-stabilizing drugs. Relatively little is known about the neural circuitry of mania. As noted earlier, both bipolar and unipolar depressed patients show structural deficits in the ventral prefrontal cortex. 13 There is also evidence that ventral frontal cortex activation deficits are a tonic feature of bipolar disorder, ie, unrelated to behavioral state. 61 These ventral regions may contribute to the inhibition of prepotent or impulsive responses. [62] [63] [64] In contrast, limbic targets of ventral frontal cortex, including the dorsal anterior cingulate gyrus and ventral striatum appear to show increased metabolic activity when patients with bipolar disorder are in the manic state. 21 Since the projections from the orbital frontal cortex to the limbic structures are glutamatergic, mania-related hyperactivity may be suggestive of excessive activation of glutamatergic cortico-limbic pathways. Thus, the hypothesis that a mood-stabilizing drug might attenuate glutamate release or the consequences of glutamate release could be consistent with these data from functional neuroimaging studies.
Mood stabilizers appear to attenuate glutamatergic function through multiple mechanisms. Repeated administration of lithium, the prototype mood stabilizer, may promote the uptake of glutamate from the synapse, 65 attenuate the function of glutamate receptors 66 and reduce the function of intracellular signaling cascades that are activated by the binding of glutamate to its receptors. 67 Anticonvulsant and voltage-sensitive calcium channel antagonist mood stabilizers appear to reduce glutamate release, to attenuate postsynaptic excitability and to inhibit intracellular signaling downstream from glutamate receptors. [68] [69] [70] [71] [72] [73] [74] Within the class of anticonvulsant medications, there is variability with respect to their relative antidepressant and antimanic efficacy. Future research will be needed to determine those properties of anticonvulsant agents that are distinctly relevant to each action.
Serotonin-2A (5HT 2A ) receptor antagonists and group II metabotropic glutamate receptor (mGluRII) agonists might also be predicted to have mood-stabilizing activity. 5HT 2A agonists, such as the hallucinogenic drugs, appear to stimulate cortical glutamate release via receptors located on thalamocortical terminals and the apical dendrites of cortical pyramidal neurons. [75] [76] [77] This stimulatory effect is blocked by 5HT 2A receptor antagonists or mGluRII agonists. 78 If reduction in glutamatergic drive contributes to the suppression of mania, and if 5-HT 2A antagonism has antidepressant consequences, 79 then blockade of 5HT 2A receptors might contribute to the mood-stabilizing effects associated with the atypical antipsychotics, a class of drugs with potent 5-HT 2A receptor antagonism. 80, 81 The hypothesis that mood stabilizers might attenuate Figure 3 Evidence of acute antidepressant effects of ketamine in patients with major depression. Transient euphoric effects, assessed using a visual analog scale for 'high' and psychotogenic effects, reflected in the total scores on four items used to assess psychosis (conceptual disorganization, hallucinatory behavior, suspiciousness and unusual thought content) on the BPRS are temporally dissociated from the antidepressant effects of ketamine in these patients. These data were analyzed by repeated measures ANOVA and the drug by time interaction for each outcome measure was highly significant (P Ͻ 0.005). Presented data reflect the mean scores at each timepoint. Abbreviations: HDRS: Hamilton Depression Rating Scale; VAS: Visual Analog Scale; BRPS: Brief Psychiatry Rating Scale. Adapted from Berman et al. 60 cognitive deficits and mood disturbances associated with glutamatergic hyperactivity appears to be consistent with human laboratory studies. Systemic administration of NMDA antagonists stimulate glutamatergic activity in prefrontal cortex and limbic structures. [82] [83] [84] In humans, the cognitive and behavioral effects of NMDA antagonists were studied with the aim of understanding glutamatergic dysfunction in schizophrenia. 49, 85 However, these studies may also have relevance to mania. Consistent with the animal studies, subanesthetic doses of the NMDA antagonist, ketamine, activate frontal cortical glucose metabolic rate or blood flow, as measured with positron emission tomography and functional magnetic resonance imaging. [86] [87] [88] [89] Every mood-stabilizing agent studied to date appears Molecular Psychiatry to attenuate a component of the behavioral effects of ketamine in humans. For example, lamotrigine and nimodipine attenuate the magnitude of the psychosis, attention impairment and memory impairment produced by ketamine in human subjects. 90, 91 In contrast, lamotrigine may have increased the euphoric and stimulatory effects of ketamine. It is not yet clear whether the enhanced euphoric response to ketamine reflects a limitation of lamotrigine in treatment of mania or its prominent antidepressant effects. 92 Direct antidepressant effects of lamotrigine would be consistent with the antidepressant effects of NMDA receptor antagonists. Reductions in membrane depolarization by blockade of voltage-gated ion would be expected to reduce the extent to which these receptors were in the 'active state,' where they were responsive to the binding of glutamate and glycine. 91 Preliminary analyses also suggest that the alpha-2 adrenergic agonist, guanabenz, attenuates the psychotic and cognitive effects of ketamine in healthy subjects. 93 Another alpha-2 agonist, clonidine, has been reported to have some antimanic effects, although perhaps less than lithium. 94, 95 Pretreatment of healthy subjects with atypical antipsychotics has generated mixed data. One preliminary report with olanzapine 10 mg was negative, 96 while another study found that sertindole pretreatment attenuated the psychotic and cognitive effects of ketamine in healthy subjects. 97 Lastly, pretreatment of healthy subjects with lorazepam 2 mg, orally, did not reduce the psychotic responses to ketamine, although there was some evidence of reductions in dissociation-like perceptual alterations. 98 Higher lorazepam doses may be needed to demonstrate further attenuation of ketamine effects 99 or antimanic effects.
100,101
Summary In summary, the limited existing data suggest that NMDA antagonists may have rapid antidepressant effects in patients with major depressive disorder. Mood-stabilizing agents may exert their antimanic and antidepressant actions, in part, via reductions in glutamate release or membrane depolarization. The importance of these findings may be several-fold. Firstly, it is important to explore the possibility that NMDA receptor antagonism would reduce symptoms in treatment-refractory patients or provide for a more rapid onset of antidepressant activity than is currently available. Secondly, reductions in glutamatergic function might produce effective mood stabilization, ie, antidepressant and antimanic consequences. Thus, as these medications are better studied, they may have a particularly prominent role in treating depression in patients with bipolar disorder.
Antidepressants and mood stabilizers as modulators of GABA function
Cortical GABA deficits in mood disorders
Recent studies suggest that major depressive disorder is associated with reductions in GABAergic trans-mission. 7 Earlier studies had suggested that plasma and cerebrospinal fluid GABA levels were reduced in depressed patients 102 and depressed alcohol-abusing patients. 103 However, the relationship between these findings and GABA levels within cortical regions was unclear. Similarly, postmortem studies now suggest that mood disorders are associated with reduced numbers of GABA neurons in layer II of the orbitofrontal cortex. 15 Mechanisms that might promote the failure of GABA neurons to develop or to be preferentially eliminated in depressed patients are not clear. GABA neurons are responsive to brain derived neurotrophic factor, 104 and stress-related deficits in brain derived neurotrophic factor 105 could contribute to deficits in GABA function. Alternatively, there is increasing interest in the possibility that affective disorders may be associated with reduced function of genes, such as bcl-2, that might be protective against apoptosis, which is a natural neurotoxic process. 106 This hypothesis would be consistent with the neuroprotective effects of some mood-stabilizing agents. 107 Similarly, stress-related reductions in neurogenesis might deplete brain GABA neuronal populations if these neuronal populations undergo substantial turnover.
Given the potential value of monitoring the integrity of GABA systems, there has been a need to develop neuroimaging methods to monitor GABAergic regulation in humans. The capacity to measure cortical GABA levels in humans in vivo was made possible by the development of a 1 H-MRS technique, which involved editing of the MRS spectrum to remove the signals of overlaying amino acids, such as glutamate and glutamine, as described elsewhere. 108 In combination with drugs that block GABA degradation, 1 H-MRS might provide a measure of GABA synthesis, ie, GAD activity. 109 Alternatively, GAD activity may soon be measured directly in humans by studying the rate of the incorporation of 13 C into GABA in 13 C-MRS studies of 13 C-glucose infusion. 29 Measurement of cortical GABA levels appears to discriminate between unipolar and bipolar depressed patients. In the initial study, cortical GABA levels in antidepressant-free depressed patients were substantially reduced relative to a healthy comparison group. 110 Subsequent studies suggest that cortical GABA level reductions are observed in unipolar, but not bipolar depressed patients. 26 Further, among unipolar depressed patients, reductions were most prominent in patients with melancholic or psychotic depressions as compared with patients meeting criteria for the atypical depression subtype (Sanacora G et al, unpublished data) . Among patients with major depression, GABA levels correlated inversely with cortical glutamate levels within the same cortical voxel. In these studies, cortical glutamate levels, in turn, were positively correlated with the levels of Nacetyl-aspartate within the cortical voxel. These data may support a prominent neuronal contribution to both the glutamate and GABA signals as measured with 1 H-MRS. To the extent that measurements of cortical GABA levels differentiate subtypes of depressed patients, it is possible that these assessments may have prognostic significance with respect to course of illness or prediction of treatment response. As effective antidepressant treatments for bipolar depressed patients that are devoid of the risk of stimulating mania are identified, the value of objective tools for discriminating unipolar and bipolar depressed patients is increased.
Reductions in occipital cortex GABA levels are not unique to major depression. One study, for example, found that occipital cortex GABA levels were reduced in patients with panic disorder. 111 These patients did not have clinically significant levels of depression. However, GABA levels were reduced to the greatest extent among panic disorder patients who had a history of panic disorder or major depression in a firstdegree relative. Thus, it is possible that reductions in cortical GABA levels may reflect a genetic diathesis related to the vulnerability to both panic disorder and depression. This diathesis may be consistent with the relatively high comorbidity of panic disorder and major depression in the clinical literature. 112, 113 However, it is noteworthy that panic disorder and major depression are both associated with reductions in cortical GABA level, while atypical depression, a form of depression associated with heightened mood reactivity and panic attacks, is not (Sanacora G et al, unpublished data) . In this regard, atypical depression and bipolar depression are similar. Thus, future studies will be needed to evaluate possible relationships between atypical depression and bipolar spectrum disorders.
Premenstrual dysphoric disorder (PMDD) appears to be associated with menstrual-cycle phase-related disturbance in cortical GABA regulation. Healthy women demonstrate a reduction in cortical GABA levels from a peak in the follicular phase to a trough in the late luteal phase. This change is hypothesized to reflect a response to cyclical changes in estrogen, progesterone and their neuroactive derivatives that have known modulatory effects on glutamate and GABA receptor function. Women with PMDD exhibit reductions in occipital cortex GABA levels during the follicular phase, when they are typically asymptomatic. 114 Unlike healthy women, women with PMDD show no cyclic decline in cortical GABA levels across the menstrual cycle, and they may increase GABA levels in the transition from follicular to luteal phase. These PMDDrelated changes could be related to menstrual-cycle phase-related alterations in the levels of estrogen, progesterone or their neuroactive precursors and metabolites. [115] [116] [117] [118] Electroconvulsive therapy and serotonin reuptake inhibition reduce cortical GABA deficits in depressed patients Antidepressant treatments appear to eliminate the deficit in cortical GABA levels associated with major depressive disorder. Older preclinical literature 7 indicated that reductions in cortical GABA levels found in animal models of depression 119 were reversed by anti-depressant treatments, including electroconvulsive therapy. 120 Similarly, effective electroconvulsive therapy was long known to raise seizure threshold, an effect hypothesized to reflect enhancement of cortical GABA function. [121] [122] [123] Initial studies evaluating the impact of electroconvulsive therapy and serotonin reuptake inhibition suggest that both treatments eliminate the GABA deficit in depressed patients. 124, 125 In patients receiving electroconvulsive therapy, the degree of GABA elevation correlated with the magnitude of the treatment-related rise in seizure threshold. In patients receiving serotonin reuptake inhibition treatment, the magnitude of the treatment-related rise in cortical GABA level correlated with the degree of occipital cortex GABA deficit.
Mood-stabilizer effects on cortical GABA levels
Although mood-stabilizer effects on cortical GABA levels have not been studied in patients with mood disorders, anticonvulsant effects have been described in epileptic patients. Current studies suggest that effective pharmacological control of epilepsy raises cortical GABA levels. [126] [127] [128] [129] However, some agents have specific actions that increase GABA levels. For example, vigabatrin blocks GABA transaminase, the principal GABA catabolic enzyme. This drug raises occipital cortex GABA levels in epilepsy patients. It is currently unclear whether other anticonvulsants that raise cortical GABA levels in epilepsy patients, including topiramate, gabapentin and valproic acid will raise these levels in other groups. For example, benzodiazepines appear to raise cortical GABA levels in the context of seizure control. In contrast, acute and chronic benzodiazepine administration appear to reduce cortical GABA levels in healthy subjects (Goddard et al, unpublished data) . It is possible that drugs such as benzodiazepines that act by directly enhancing GABA receptor function may produce inhibition of glutamic acid decarboxylase, and thereby reduce GABA levels. Thus, mood stabilizers, as a group, may show diverse effects on cortical GABA levels. However, drug-specific modulations of GABA levels may be an important reflection of their efficacy.
Summary
Melancholic and psychotic patients with major depressive disorder demonstrate a reduction in occipital cortex GABA levels. These reductions are not observed in bipolar depressed patients or patients with atypical depression. Electroconvulsive therapy and antidepressant treatment raise GABA levels in depressed patients, suggesting that normalizing GABA function may contribute or reflect effective antidepressant treatments. Mood-stabilizing anticonvulsant medications raise cortical GABA levels in patients with seizure disorders, and are associated with seizure control. Thus, GABA systems may also be a target for the treatment of bipolar disorder. Future research will need to explore GABAergic regulation in multiple cortical regions. It will also be important to study molMolecular Psychiatry ecular mechanisms that might link GABAergic regulation to mood disorders and their treatment.
Amino acid neurotransmission and mood disorders: expanding the horizons of research
The central thesis of this review is that amino acid neurotransmitter system dysfunction may contribute to the pathophysiology of mood disorders, and that correction of this dysfunction could be an important treatment aim for these disorders. The literature cited in support of these hypotheses emerged before technologies could adequately evaluate them in patients. Subsequent increases in the sophistication of laboratorybased psychopharmacology studies, the development and application of informative neuroimaging technologies and the explosion in molecular and systems neuroscience research make the hypotheses linking amino acid neurotransmission to mood disorders and their treatment now seem more compelling. As interest in amino acid neurotransmitters grows, there is also increasing opportunity to integrate amino acid hypotheses with more established theories involving monoaminergic, peptidergic and glucocorticoid effects, as well as more recent theories involving neurotrophins, intracellular signal transduction and changes in gene expression. The integrative picture that emerges links the dysregulation within cortico-limbic circuits to atrophy, apoptosis and neurogenesis deficits. In addition, structural deficits are now linked to dysfunction of amino acid neural circuitry in mood disorders. It would be surprising if further developments in treatments targeting amino acid neurotransmission were far behind.
